That is very important, due to the fact that the way a protein in the human body folds identifies if a pharmaceutical will be able to bind to that protein and be efficient. To put it simply, we need to know how these proteins fold if we want a drug to work. Historically, this has actually been a trial-and-error process (jeff brown). Today, Alpha, Fold can predict protein folding with 92. 4% accuracy. That's going to make it a lot easier to create drugs that do what they're designed to do. This was an advancement almost no one discovered. However it's going to have extensive implications for treating disease. I anticipate that Alpha, Fold will be 98% precise by the end of 2021.
And, of course, there will be plenty of financial investment opportunities in this area, too. Shifting subjects It's going to be a good year for bitcoin. I'm bullish on it in 2021 (diplomatic relations). That stated, I still believe bitcoin will continue to be unpredictable. We're close to all-time highs. I wouldn't be shocked if it pulled back possibly substantially before going greater - jeff brown genome sequencing stock. I have actually been covering bitcoin for a long period of time now. Among the first research reports I ever published was on bitcoin. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that preliminary recommendation, I entitled my report "What's the Big Offer With Bitcoin?" That reveals you where the discussion was at the time. We were mostly informing readers. However that's not the big question any longer. Now we're seeing institutional money finally take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, niche enterprise. Mass, Mutual is a relied on 170-year-old organization. So think about that. In 5 years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
And that's a huge factor I'm bullish on it this year. jeff brown 1 biotech. Regards, Jeff Brown, Editor, The Bleeding Edge I have a bonus offer prediction 2020 was a record year for IPOs. 552 U.S. business went public the most in more than 20 years. These companies raised an overall of $172 billion. That's an all-time high beating the previous yearly record by 43%. I forecast 2021 will be another record year in IPOs. There are so lots of terrific private business on the verge of hitting the public markets And I have actually been working on a new way for you to invest even before these business go public.
This chance has been building over the last few years. I can't wait to inform you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Occasion to find out all the information. Go right here to schedule your spot free of charge.
Emma Walsh here, managing editor of the Journal. Regular Diary readers know that tech isn't our normal beat (black sea). And when it pertains to tech investing, we leave it to the specialists. Luckily, we have numerous such experts in our Rolodex. Our colleague Jeff Brown will be familiar to our long time readers. He is among the most accomplished tech investing specialists we know (last year). In truth, he had numerous triple-digit returns in his Brownstone Research study portfolios last year. Here's what Jeff thinks the tech sector will bring us in 2021 Each year, I like to have a look at the big photo and forecast what's simply around the corner.
That consists of things like 5G networks, biotech, synthetic intelligence, and a lot more. These patterns are experiencing rapid development and creating unbelievable opportunities for investors. I wish to make sure all our readers are gotten ready for what's next. And with that in mind, let me draw the photo of what I see can be found in the next 12 months Our new 5G (fifth-generation) cordless networks are a topic I have actually been covering for years now. angel investor. However regardless of what lots of readers may think, this is a trend that's simply getting going. Despite the fact that the COVID-19 pandemic disrupted supply chains in 2015, a remarkable 250 million 5G-enabled devices were still offered.
And all of this eventually caused Apple postponing the release of the 5G-enabled i, Phone 12 by two months (tech predictions). Losing 2 months of manufacturing and sales really impacts the number of 5G gadgets are sold in the fiscal year. When you consider all of that, offering 250 million systems is amazing. More importantly, the hold-ups triggered by the pandemic created a lots of suppressed demand. And that demand is now going to be pressed into 2021. In truth, I anticipate that more than 500 million 5G devices will be shipped in 2021 - bleeding edge. And that's not my only 5G prediction When I've talked about 5G in the past, I've explained its three various stages.
In Stage 2, 5G gadgets go on sale. 5G phones and other products begin to reach customers. And in Phase Three, 5G services begin to be offered (jeff brown biotech genome sequencing). That's when we start to see applications running on 5G networks. Think of things like massive multiplayer games over a cellphone. That's not possible with 4G. It will be with 5G. And my second 5G prediction for 2021 is that we will begin Phase 3 by this summer. This starts something of a virtuous cycle: The majority of people don't actually appreciate the technology. However they will care if there are interesting applications that can only be accessed with a 5G phone.
That causes more 5G apps being established. In reality, 5G is going to open up a suite of incredible applications: self-driving cars and trucks, the Internet of Things, robotic surgical treatment, and more. All of these innovations need 5G. The financial investment opportunities moving forward will be huge. Stepping far from 5G, the next crucial innovation I visualize in 2021 is CRISPR genetic modifying. CRISPR means "clustered routinely interspaced short palindromic repeat." It's a mouthful. But it's one of the most exciting developments in biotechnology. At a high level, CRISPR is an innovation that can modify our genetic makeup as if it were software application.
The program can crash or not work properly. CRISPR uses a comparable concept however with our genetic code. "Typos" in our genome can cause disease. CRISPR can remedy these "typos." For several years, CRISPR was primarily a niche innovation that wasn't well understood. And throughout that time, there were really just three business operating in this space. But things are altering. CRISPR is no longer simply theoretical. We're seeing actual results. We're treating illness and seeing that this innovation simply works. And as a result, a "2nd crop" of early-stage CRISPR business is going public and providing incredible returns. This entire market is efficiently a greenfield opportunity.
There's room for numerous companies to exist in this area. jeff brown biotech stock pick for 2020. And there will be more. That's my forecast for CRISPR in 2021. I anticipate that two or 3 more genetic modifying companies will hold their IPOs. Sticking to biotechnology, we are seeing amazing things happening at the merging of biotech and artificial intelligence (AI). Google's AI subsidiary, Deep, Mind, simply revealed at the end of 2020 that its newest Alpha, Fold software application can precisely anticipate the folding of a protein based exclusively on its amino acid sequence with 92. 4% precision. That's important since the method a protein in the human body folds determines if a pharmaceutical will be able to bind to that protein and work.
Historically, this has actually been a trial-and-error procedure. Today, Alpha, Fold can predict protein folding with 92. 4% accuracy. That's going to make it a lot easier to create drugs that do what they're created to do. And here's my next prediction. I anticipate that Alpha, Fold will be 98% precise by the end of 2021. And we will see not simply one but several drug treatments produced using this innovation. This was among those advancements that nearly no one discovered. But it's going to have profound implications for curing disease. And, of course, there will be plenty of financial investment chances in this area, too.
It's going to be a great year for bitcoin. I'm bullish on it in 2021. That stated, I still believe bitcoin will continue to be unpredictable. We're close to all-time highs. I wouldn't be shocked if it pulled back possibly considerably prior to going greater. I have actually been covering bitcoin for a very long time now. One of the first research reports I ever released was on bitcoin - angel investor. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on financial investment for any person who followed my recommendation. However at the time of that preliminary recommendation, I entitled my report, "What's the Big Offer With Bitcoin?" That shows you where the conversation was at the time.
However nobody is asking that concern anymore. Now, we're seeing institutional cash lastly taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, specific niche enterprise. biotech stock. Mass, Mutual is a 150-year-old institution. So believe about that. In 5 years, we went from educating readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. And that's a big reason that I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another reward forecast In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown deserves about $27. 5 million and declares the details depends on date as of February 2021, however we could not individually confirm this claim. Given Jeff Brown's past, he likely has a substantial net worth, however we can't hammer down a precise figure at this moment. Brown is best understood for his sage-like ability to pick winning innovation stocks. He spent more than 25 years researching technology companies like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's extensive experience offers him an outstanding point of view on the marketplace. He's always on the hunt for new chances, and he shares many of his best picks in the Future Report.
That's full marks, however it's not ridiculously reasoned. Brown has an excellent reputation as a stock-picker, and he successfully predicted some of the greatest economic occasions of the past 20 years. Although he doesn't appear to release his picks to the general public, the service's success is a direct indication of Brown's stock-picking prowess. Nobody on Wall Street gets it right every time, however Jeff Brown's accurate forecasts have made him legions of devoted followers. That states a lot about his capability. The Future Report is published by Brownstone Research, a prominent financial research study publisher. Brownstone Research offers a number of research services with a wide array of specializations - korean actress.
The company is also connected with Bonner & Partners, another well-respected research study publisher - longtime readers. On its site, Brownstone states its objective is to offer retail investors with professional-grade research: "For too long, the best investment research has actually not been offered to specific financiers. It has been typically reserved for financial investment banks, hedge funds, private equity, and high-net-worth customers. jeff brown biotech stock. The objective of Brownstone Research is to make that type of proprietary research study offered to any investors looking to get an edge in the marketplaces. The objective is simple to provide distinct and lucrative financial investment research found nowhere else." -Brownstone Research website excerpt from the Jeff Brown is the creator of Brownstone Research study, and he likewise acts as the firm's Chief Financial investment Analyst.
With Brown guiding the ship, Brownstone Research is a powerhouse publisher with lots to offer its customers. After years of consistent success at the helm of top-tier business like Tesla and Area, X, Elon Musk is a family name throughout the majority of America. If you understand even a little bit about the market, you know that he has a track record as a King Midas of sorts. jeff brown biotech genome sequencing. Everything he touches turns to gold! Jeff is aware of Elon Musk's executive expertise, so he constantly has an eye out for the Silicon Valley rock star's next move. This time, Jeff has an early lead on Elon's next big task.
In truth, Brown believes S.A.V. jeff brown biotech stocks. could be "the most significant trend of the 2020s, and he's not alone. Take a look at these quotes from other widely known S.A.V. bulls: Elon's next huge act will be marrying 2 innovative technologies: expert system and electrical automobiles. Musk hopes the combination will help him develop the first fully-autonomous, self-driving cars ever. It's nothing short of the vehicle industry's Holy Grail. As you know, electrical vehicles and self-driving automobile stocks have been huge this year, however the Wall Street device has been huge on hype without much tangible result. Regardless of a drastic increase in competition over the previous few years, Brown still believes Musk has the very best opportunity of putting everything together.
tech might be the magic string that ties everything together. S.A.V. means Shared Autonomous Automobile, and it could be the future of transport. Essentially, this technology would allow you to rent out your cars and truck as an autonomous, self-driving taxi when you're not utilizing it. You simply leave the automobile and press a button on an app that informs the cars and truck to "join the fleet." Next thing you know, you're unwinding on your sofa while your car shuttles ride-sharers around town. Best of all, you get to keep a substantial chunk of the revenues. It sounds outrageous, but it could be closed than you think.